ECT2 and cancer: Early observations suggested that ECT2 is auto-inhibited in the nucleus by its N-terminal BRCT domains 26, 27, whereas a recent study suggested that the mechanisms that account for ECT2 in driving cancer progression also involve its nuclear GEF activity 15, implying that the active and inactive pool of nuclear ECT2 possibly exists simultaneously or switches dynamically.